

Limited Submission Funding Opportunities – updated 11/05/21

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. St. Baldrick's Foundation

<https://www.stbaldricks.org/for-researchers>

MGH LOI Deadline: 11/08/21

Foundation LOI Deadline: 12/03/21

Application Deadline: 2/18/22

The St. Baldrick's Foundation is proud to fund lifesaving research throughout the world, awarding grants that focus on all major types of childhood cancers.

St. Baldrick's donors and volunteers have enabled the foundation to fund over \$200 million in grants, allowing the foundation to fund more in childhood cancer research grants than any organization except

Limited Submission Funding Opportunities – updated 11/05/21

the U.S. government. Every grant goes through a rigorous scientific review process, ensuring every dollar has the greatest possible impact for children with cancer. Funding Priorities include new discovery research, translational research and early phase clinical trials, phase 3 clinical trials and infrastructure support, and education of new pediatric oncology researchers.

MGH may submit one LOI/application in each funding categories. **In the internal LOI, please indicate what category you will be submitting under.**

2. Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/pa-files/PAR-21-337.html>

MGH LOI Deadline: 11/16/21

NIH Application Deadline: 1/26/22

The National Center for Advancing Translational Sciences (NCATS) will award Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grants for the Clinical and Translational Science Awards (CTSA) Program (T32) to eligible institutions to enhance predoctoral research training of individuals seeking a PhD or an equivalent research health professional degree and help ensure a heterogeneous pool of clinical and translational scientist trainees who are equipped with the knowledge, skills and abilities to advance diagnostics, therapeutics, clinical interventions, and behavioral modifications aimed at improving health.

Applicants interested in providing short-term research experiences to health professional participants must apply to the companion NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs (R25) ([PAR-21-339](#)). A short-term research experience is one where the participant is full-time (40 hours per week) for a period of 10 to 15 weeks, or as specified by the sponsoring institution in accordance with its own policies.

The proposed institutional research training program may complement other ongoing research training and career development programs at the applicant institution but must be clearly distinct from related programs currently receiving Federal support.

This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial on which the PI is a mentor or co-mentor. NIH strongly supports training towards a career in clinically relevant research and so gaining experience in clinical trials under the guidance of a mentor or co-mentor is encouraged.

NIH requires each applicant to submit a subsequent UM1 application ([PAR-21-293](#): Clinical and Translational Science Award) concurrently with the T32 application. MGH is limited to one T32 application per institution. If an applicant has not submitted a companion UM1, the T32 will not be reviewed.

When submitting your internal LOI to ECOR, please include the title of your UM1 application.

Limited Submission Funding Opportunities – updated 11/05/21

3. Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/pa-files/PAR-21-338.html>

MGH LOI Deadline: 11/16/21

NIH Application Deadline: 1/26/22

The National Center for Advancing Translational Sciences (NCATS) will award Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Institutional Research Training Grants for the Clinical and Translational Science Awards (CTSA) Program (T32) to eligible institutions to enhance postdoctoral research training of individuals with doctoral degrees (these include, but are not limited to, the following: D.M.D., DC, DO, DVM., OD, DPM, ScD, EngD, DrPH, DNSc, DPT, PharmD, ND [Doctor of Naturopathy], DSW, PsyD, as well as a doctoral degree in nursing research) and help ensure a heterogeneous pool of clinical and translational scientists trainees are equipped with the knowledge, skills and abilities to advance diagnostics, therapeutics, clinical interventions, and behavioral modifications that improve health.

NCATS will not accept applications proposing combined predoctoral and postdoctoral training under this FOA. Applications proposing predoctoral research training should apply to the Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program ([PAR-21-337](#)).

The proposed institutional research training program may complement other ongoing research training and career development programs at the applicant institution, but must be clearly distinct from related programs currently receiving Federal support.

This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial on which the PI is a mentor or co-mentor.

NIH requires each applicant to submit a subsequent UM1 application ([PAR-21-293](#): Clinical and Translational Science Award) concurrently with the T32 application. MGH is limited to one T32 application per institution. If an applicant has not submitted a companion UM1, the T32 will not be reviewed.

When submitting your internal LOI to ECOR, please include the title of your UM1 application.

4. National Hemophilia Program Coordinating Center (HRSA)– NEW!

<https://www.grants.gov/web/grants/view-opportunity.html?oppId=334384>

MGH LOI Deadline: 11/22/21

Sponsor Application Deadline: 1/24/22

The Health Resources and Services Administration (HRSA) is accepting applications for two separate projects to be awarded in fiscal year (FY) 2022 - HRSA-22-068, the Regional Hemophilia Network (RHN) (Project 1) and HRSA-22-079, the National Hemophilia Program Coordinating Center (NHPCC) (Project 2). The purpose of these programs is to improve access to coordinated, evidence-based care for patients with hemophilia and related bleeding or clotting disorders and their families.

HRSA-22-079: The National Hemophilia Program Coordinating Center (NHPCC) (Project 2): One national coordinating center will strengthen the capacity of the RHN and HTC comprehensive care teams through

Limited Submission Funding Opportunities – updated 11/05/21

targeted technical assistance (TA), programmatic support, and data collection to assess patient outcomes.

5. Emerging Strategies to Improve Health Outcomes for People Aging with HIV: Demonstration Sites – NEW!

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=334407>

MGH LOI Deadline: 11/30/21

Sponsor Application Deadline: 1/25/22

This NOFO, HRSA-22-028 Emerging Strategies to Improve Health Outcomes for People Aging with HIV: Demonstration Sites, will fund up to 10 demonstration sites to identify, implement, refine, and evaluate emerging strategies to comprehensively screen and manage comorbidities, geriatric conditions, behavioral health, and psychosocial needs of people 50 years and older with HIV with the existing resources and infrastructure of organizations funded through the RWHAP. This funding opportunity will support organizations that have the capacity and infrastructure to successfully execute the project and that have some experience implementing emerging strategies to comprehensively screen and manage comorbidities, geriatric conditions, behavioral health, and psychosocial needs of people 50 years and older with HIV. Working in partnership with the evaluation provider and capacity-building provider, the demonstration sites will participate in evaluating their strategies and developing replication tools for use by other RWHAP recipients and subrecipients.

The demonstration sites must provide comprehensive screening and management of comorbidities, geriatric conditions, behavioral health, and psychosocial needs of people 50 years and older with HIV or have an agreement with an organization that can provide these services (referred to as partner organization in the NOFO).

6. Emerging Strategies to Improve Health Outcomes for People Aging with HIV: Capacity-Building Provider – NEW!

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=334406>

MGH LOI Deadline: 11/30/21

Sponsor Application Deadline: 1/25/22

This NOFO, HRSA-22-027 Emerging Strategies to Improve Health Outcomes for People Aging with HIV: Capacity-Building Provider, will provide technical assistance and capacity development to up to 10 demonstration sites to identify, implement, refine, and evaluate emerging strategies to comprehensively screen and manage comorbidities, geriatric conditions, behavioral health, and psychosocial needs of people 50 years and older with HIV, within the context of the RWHAP; and communicate and dissemination information regarding the initiative. The capacity- building provider will coordinate and implement all activities and products to align with the HAB implementation science framework.

The technical assistance and capacity development activities will consist of learning collaboratives, one-on-one technical consultation, and peer-to-peer exchanges related to identifying, implementing, and refining emerging strategies to comprehensively screen and manage comorbidities, geriatric conditions, behavioral health, and psychosocial needs of people 50 years and older with HIV. The technical assistance and capacity development activities should facilitate the implementation and refinement of the emerging strategies with the existing resources and infrastructure of organizations funded through the RWHAP. The capacity-building provider will communicate information about the implementation and progress of the initiative throughout its duration and disseminate the evaluation findings and replication tools.

Limited Submission Funding Opportunities – updated 11/05/21

7. Emerging Strategies to Improve Health Outcomes for People Aging with HIV: Evaluation Provider – NEW!

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=334408>

MGH LOI Deadline: 11/30/21

Sponsor Application Deadline: 1/25/22

The Health Resources and Services Administration (HRSA) is accepting applications for the fiscal year (FY) 2022 Ryan White HIV/AIDS Program (RWHAP) Special Projects of National Significance (SPNS) Program initiative, Emerging Strategies to Improve Health Outcomes for People Aging with HIV.

This NOFO, HRSA-22-029 Emerging Strategies to Improve Health Outcomes for People Aging with HIV: Evaluation Provider, solicits a recipient who will develop and carry out a multi-site evaluation that includes a customized site-specific evaluation for each of the 10 demonstration sites (HRSA-22-028) that will identify, refine, and implement emerging strategies to comprehensively screen and manage comorbidities, geriatric conditions, behavioral health, and psychosocial needs of people 50 years and older with HIV, within the existing resources and infrastructure of organizations funded through the RWHAP. In addition to the site-specific components, the evaluation will include cross-site components that are consistent across all of the demonstration sites. The evaluation provider's activities and products will align with the HAB implementation science framework. Throughout this initiative, the evaluation provider will work closely with the demonstration sites (HRSA-22-028) and capacity-building provider (HRSA-22-027). The capacity-building provider will lead and implement the dissemination plan, which will include the evaluation findings produced by the evaluation provider.

8. Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)

<https://grants.nih.gov/grants/guide/pa-files/PAR-21-321.html>

MGH LOI Deadline: 12/01/21

NIH Application Deadline: 1/25/22

This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this FOA are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community

Limited Submission Funding Opportunities – updated 11/05/21

9. Genomic Curriculum Development for Medical Students (R25 Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/pa-files/PA-21-312.html>

MGH LOI Deadline: 12/06/21

NIH Application Deadline: 1/25/22

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on **Curriculum Development**. This NHGRI R25 program offers to support the development of curricula for Master of Science (M.S.) degree programs in genomics, genomic medicine and/or genomic informatics for medical students. Specifically, this FOA will support the development of curriculum designed to be freely available, at no cost to the broader community to enhance training in genomics for medical students.

10. SUNBEAM – Analysis and Bioinformatics Center (ABC) (UM1 Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-060.html>

MGH LOI Deadline: 12/08/21

NIH LOI Deadline: 1/15/22

NIH Application Deadline: 2/15/22

The purpose of the SUNBEAM - Analysis and Bioinformatics Center (SUNBEAM-ABC) is to establish a mechanistic omics center to support the birth cohort study Systems Biology of Early Atopy (SUNBEAM). The center will assay biologic samples collected within the SUNBEAM cohort using omics and systems biology approaches to identify determinants of atopic disease, focusing on food allergy and atopic dermatitis (AD) in newborns, infants, and very young children. SUNBEAM-ABC will support the SUNBEAM birth cohort study by providing analytic infrastructure for a comprehensive understanding of molecular and cellular pathways that contribute to atopic disease development and to identify early predictive biomarkers.